Clinical Trial Update: A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A prospective Phase 1/2 clinical trial assessing a CD3-CD20 bispecific antibody–based therapy combined with CD19-CAR T cells for relapsed or refractory B-cell n…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD19 CAR T cells
• CD3-CD20 bispecific antibody-based therapy (CD3-CD20 bispecific antibody)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: B-cell Non-Hodgkin Lymphoma | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING